RT Journal Article
SR Electronic
T1 Evidence for Behavioral Autorepression in Covid-19 Epidemiological Dynamics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.07.24308626
DO 10.1101/2024.06.07.24308626
A1 Lewis, Daniel D.
A1 Pablo, Michael
A1 Chen, Xinyue
A1 Simpson, Michael L.
A1 Weinberger, Leor
YR 2024
UL http://medrxiv.org/content/early/2024/06/09/2024.06.07.24308626.abstract
AB It has long been hypothesized that behavioral reactions to epidemic severity autoregulate infection dynamics, for example when susceptible individuals self-sequester based on perceived levels of circulating disease. However, evidence for such ‘behavioral autorepression’ has remained elusive, and its presence could significantly affect epidemic forecasting and interventions. Here, we analyzed early COVID-19 dynamics at 708 locations over three epidemiological scales (96 countries, 50 US states, and 562 US counties). Signatures of behavioral autorepression were identified through: (i) a counterintuitive mobility-death correlation, (ii) fluctuation-magnitude analysis, and (iii) dynamics of SARS-CoV-2 infection waves. These data enabled calculation of the average behavioral-autorepression strength (i.e., negative feedback ‘gain’) across different populations. Surprisingly, incorporating behavioral autorepression into conventional models was required to accurately forecast COVID-19 mortality. Models also predicted that the strength of behavioral autorepression has the potential to alter the efficacy of non-pharmaceutical interventions. Overall, these results provide evidence for the long-hypothesized existence of behavioral autorepression, which could improve epidemic forecasting and enable more effective application of non-pharmaceutical interventions during future epidemics.Significance Challenges with epidemiological forecasting during the COVID-19 pandemic suggested gaps in underlying model architecture. One long-held hypothesis, typically omitted from conventional models due to lack of empirical evidence, is that human behaviors lead to intrinsic negative autoregulation of epidemics (termed ‘behavioral autorepression’). This omission substantially alters model forecasts. Here, we provide independent lines of evidence for behavioral autorepression during the COVID-19 pandemic, demonstrate that it is sufficient to explain counterintuitive data on ‘shutdowns’, and provides a mechanistic explanation of why early shutdowns were more effective than delayed, high-intensity shutdowns. We empirically measure autorepression strength, and show that incorporating autorepression dramatically improves epidemiological forecasting. The autorepression phenomenon suggests that tailoring interventions to specific populations may be warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH grant R37AI109593.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data sources were publicly available during the COVID-19 pandemic. Source list with links (some are no longer available): Apple mobility data- https://covid19.apple.com/mobility (no longer available) JHU COVID-19 infection and mortality data- https://github.com/CSSEGISandData/COVID-19 CDC Excess death data- https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm Google Mobility data- https://www.google.com/covid19/mobility/ Stringency Index Data- https://github.com/OxCGRT/covid-policy-tracker/tree/master/data/timeseries https://github.com/OxCGRT/USA-covid-policy I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAICAkaike Information CriterionCOVID-19COronaVIrus Disease of 2019SIRSusceptible-Infective-RemovedSIRDSusceptible-Infective-Recovered-DeceasedNPINon-Pharmaceutical Intervention